Free shipping on all orders over $ 500

SC144

Cat. No. M3001

All AbMole products are for research use only, cannot be used for human consumption.

SC144 Structure
Size Price Availability Quantity
5mg USD 50  USD50 In stock
10mg USD 85  USD85 In stock
25mg USD 170  USD170 In stock
50mg USD 280  USD280 In stock
100mg USD 450  USD450 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SC144 is the first oral active GP130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, eliminates Stat3 phosphorylation and nuclear translocation, and further inhibits downstream target gene expression. SC144 inhibited signal transduction induced by GP130 ligand. SC144 induces apoptosis of human ovarian cancer cells.

Protocol (for reference only)
Cell Experiment
Cell lines OVCAR-8, OVCAR-5, OVCAR-3, Caov-3, SKOV-3, HEY NCI/ADR-RES
Preparation method MTT assay
Concentrations ~10 μM
Incubation time 96 h
Animal Experiment
Animal models Human Ovarian Cancer OVCAR-8 Xenograft
Formulation .9% NaCl with 40% propylene glycol
Dosages 10 mg/kg daily
Administration i.p. or p.o.
Chemical Information
Molecular Weight 322.3
Formula C16H11FN6O
CAS Number 895158-95-9
Form Solid
Solubility (25°C) DMSO 15 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Tiangong Lu, et al. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer

[2] Fedora Grande, et al. Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity

[3] Shili Xu, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer

[4] Takashi Oshima, et al. Combination effects of SC144 and cytotoxic anticancer agents

[5] Carmen Plasencia, et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity

Related IL Receptor/Related Products
IL-4-inhibitor-1

IL-4-inhibitor-1 is the first IL-4 small-molecule inhibitor, with an EC50 of 1.81 µM. IL-4-inhibitor-1 features a nicotinonitrile scaffold with micromolar affinity and potency for the cytokine and disrupts type II IL-4 signaling in cells.

LY3471851

LY3471851 (Rezpegaldesleukin, NKTR-358) is a novel, first-in-class selective regulatory T-cell (Treg) inducing IL-2 conjugate.

13-Methylberberine chloride

13-Methylberberine chloride is a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS.

HB0017

HB0017 is a monoclonal antibody that targets interleukin-17 (IL-17) and selectively binds IL-17A, thereby preventing IL-1717A from binding to its receptor.

Rademikibart

Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases.

  Catalog
Abmole Inhibitor Catalog




Keywords: SC144 supplier, IL Receptor/Related, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.